Pharming Group’s (PHAR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research note published on Wednesday,Benzinga reports. The firm currently has a $37.00 price target on the stock.

PHAR has been the subject of a number of other reports. Oppenheimer reduced their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Jefferies Financial Group began coverage on Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock.

Pharming Group Trading Down 3.6 %

Pharming Group stock opened at $8.98 on Wednesday. Pharming Group has a 52-week low of $6.65 and a 52-week high of $13.20. The company has a market cap of $609.27 million, a P/E ratio of -34.55 and a beta of 0.05. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The business has a 50-day simple moving average of $8.27 and a two-hundred day simple moving average of $8.15.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.